cloudfront

Report Detail



OtherGlobal Oligonucleotide Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

  • RnM2414293
  • |
  • 14 September, 2018
  • |
  • Global
  • |
  • 120 pages
  • |
  • GIR (Global Info Research)
  • |
  • Other

Global Oligonucleotide Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

Table of Contents

    1 Oligonucleotide Therapeutics Market Overview

    • 1.1 Product Overview and Scope of Oligonucleotide Therapeutics
    • 1.2 Classification of Oligonucleotide Therapeutics by Types
    • 1.2.1 Global Oligonucleotide Therapeutics Revenue Comparison by Types (2017-2023)
  • 1.2.2 Global Oligonucleotide Therapeutics Revenue Market Share by Types in 2017
  • 1.2.3 Antisense
  • 1.2.4 Ribozymes
  • 1.2.5 Aptamers
  • 1.2.6 miRNA
  • 1.2.7 CpG/Immunostimulatory
  • 1.2.8 RNAi
  • 1.2.9 Others
  • 1.3 Global Oligonucleotide Therapeutics Market by Application
  • 1.3.1 Global Oligonucleotide Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
  • 1.3.2 Infectious Diseases
  • 1.3.3 Oncology
  • 1.3.4 Neurodegenerative Disorders
  • 1.3.5 Cardiovascular Diseases
  • 1.3.6 Kidney Diseases
  • 1.3.7 Others
  • 1.4 Global Oligonucleotide Therapeutics Market by Regions
  • 1.4.1 Global Oligonucleotide Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
  • 1.4.1 North America (USA, Canada and Mexico) Oligonucleotide Therapeutics Status and Prospect (2013-2023)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Oligonucleotide Therapeutics Status and Prospect (2013-2023)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Oligonucleotide Therapeutics Status and Prospect (2013-2023)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Oligonucleotide Therapeutics Status and Prospect (2013-2023)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Oligonucleotide Therapeutics Status and Prospect (2013-2023)
  • 1.5 Global Market Size of Oligonucleotide Therapeutics (2013-2023)
  • 2 Manufacturers Profiles

    • 2.1 Pfizer
    • 2.1.1 Business Overview
  • 2.1.2 Oligonucleotide Therapeutics Type and Applications
  • 2.1.2.1 Product A
  • 2.1.2.2 Product B
  • 2.1.3 Pfizer Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
  • 2.2 Merck
  • 2.2.1 Business Overview
  • 2.2.2 Oligonucleotide Therapeutics Type and Applications
  • 2.2.2.1 Product A
  • 2.2.2.2 Product B
  • 2.2.3 Merck Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
  • 2.3 Biogen
  • 2.3.1 Business Overview
  • 2.3.2 Oligonucleotide Therapeutics Type and Applications
  • 2.3.2.1 Product A
  • 2.3.2.2 Product B
  • 2.3.3 Biogen Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
  • 2.4 PCI Biotech
  • 2.4.1 Business Overview
  • 2.4.2 Oligonucleotide Therapeutics Type and Applications
  • 2.4.2.1 Product A
  • 2.4.2.2 Product B
  • 2.4.3 PCI Biotech Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
  • 2.5 SomaGenics
  • 2.5.1 Business Overview
  • 2.5.2 Oligonucleotide Therapeutics Type and Applications
  • 2.5.2.1 Product A
  • 2.5.2.2 Product B
  • 2.5.3 SomaGenics Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
  • 2.6 ContraVir
  • 2.6.1 Business Overview
  • 2.6.2 Oligonucleotide Therapeutics Type and Applications
  • 2.6.2.1 Product A
  • 2.6.2.2 Product B
  • 2.6.3 ContraVir Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
  • 2.7 Alnylam
  • 2.7.1 Business Overview
  • 2.7.2 Oligonucleotide Therapeutics Type and Applications
  • 2.7.2.1 Product A
  • 2.7.2.2 Product B
  • 2.7.3 Alnylam Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
  • 2.8 Regulus Therapeutics
  • 2.8.1 Business Overview
  • 2.8.2 Oligonucleotide Therapeutics Type and Applications
  • 2.8.2.1 Product A
  • 2.8.2.2 Product B
  • 2.8.3 Regulus Therapeutics Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
  • 2.9 Ionis Pharmaceuticals
  • 2.9.1 Business Overview
  • 2.9.2 Oligonucleotide Therapeutics Type and Applications
  • 2.9.2.1 Product A
  • 2.9.2.2 Product B
  • 2.9.3 Ionis Pharmaceuticals Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
  • 2.10 Gilead
  • 2.10.1 Business Overview
  • 2.10.2 Oligonucleotide Therapeutics Type and Applications
  • 2.10.2.1 Product A
  • 2.10.2.2 Product B
  • 2.10.3 Gilead Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
  • 2.11 Santaris Pharma
  • 2.11.1 Business Overview
  • 2.11.2 Oligonucleotide Therapeutics Type and Applications
  • 2.11.2.1 Product A
  • 2.11.2.2 Product B
  • 2.11.3 Santaris Pharma Oligonucleotide Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
  • 3 Global Oligonucleotide Therapeutics Market Competition, by Players

    • 3.1 Global Oligonucleotide Therapeutics Revenue and Share by Players (2013-2018)
    • 3.2 Market Concentration Rate
    • 3.2.1 Top 5 Oligonucleotide Therapeutics Players Market Share
  • 3.2.2 Top 10 Oligonucleotide Therapeutics Players Market Share
  • 3.3 Market Competition Trend
  • 4 Global Oligonucleotide Therapeutics Market Size by Regions

    • 4.1 Global Oligonucleotide Therapeutics Revenue and Market Share by Regions
    • 4.2 North America Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 4.3 Europe Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 4.4 Asia-Pacific Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 4.5 South America Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 4.6 Middle East and Africa Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

    5 North America Oligonucleotide Therapeutics Revenue by Countries

    • 5.1 North America Oligonucleotide Therapeutics Revenue by Countries (2013-2018)
    • 5.2 USA Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 5.3 Canada Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 5.4 Mexico Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

    6 Europe Oligonucleotide Therapeutics Revenue by Countries

    • 6.1 Europe Oligonucleotide Therapeutics Revenue by Countries (2013-2018)
    • 6.2 Germany Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 6.3 UK Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 6.4 France Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 6.5 Russia Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 6.6 Italy Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

    7 Asia-Pacific Oligonucleotide Therapeutics Revenue by Countries

    • 7.1 Asia-Pacific Oligonucleotide Therapeutics Revenue by Countries (2013-2018)
    • 7.2 China Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 7.3 Japan Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 7.4 Korea Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 7.5 India Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 7.6 Southeast Asia Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

    8 South America Oligonucleotide Therapeutics Revenue by Countries

    • 8.1 South America Oligonucleotide Therapeutics Revenue by Countries (2013-2018)
    • 8.2 Brazil Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 8.3 Argentina Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 8.4 Colombia Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

    9 Middle East and Africa Revenue Oligonucleotide Therapeutics by Countries

    • 9.1 Middle East and Africa Oligonucleotide Therapeutics Revenue by Countries (2013-2018)
    • 9.2 Saudi Arabia Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 9.3 UAE Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 9.4 Egypt Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 9.5 Nigeria Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)
    • 9.6 South Africa Oligonucleotide Therapeutics Revenue and Growth Rate (2013-2018)

    10 Global Oligonucleotide Therapeutics Market Segment by Type

    • 10.1 Global Oligonucleotide Therapeutics Revenue and Market Share by Type (2013-2018)
    • 10.2 Global Oligonucleotide Therapeutics Market Forecast by Type (2018-2023)
    • 10.3 Antisense Revenue Growth Rate (2013-2023)
    • 10.4 Ribozymes Revenue Growth Rate (2013-2023)
    • 10.5 Aptamers Revenue Growth Rate (2013-2023)
    • 10.6 miRNA Revenue Growth Rate (2013-2023)
    • 10.7 CpG/Immunostimulatory Revenue Growth Rate (2013-2023)
    • 10.8 RNAi Revenue Growth Rate (2013-2023)
    • 10.9 Others Revenue Growth Rate (2013-2023)

    11 Global Oligonucleotide Therapeutics Market Segment by Application

    • 11.1 Global Oligonucleotide Therapeutics Revenue Market Share by Application (2013-2018)
    • 11.2 Oligonucleotide Therapeutics Market Forecast by Application (2018-2023)
    • 11.3 Infectious Diseases Revenue Growth (2013-2018)
    • 11.4 Oncology Revenue Growth (2013-2018)
    • 11.5 Neurodegenerative Disorders Revenue Growth (2013-2018)
    • 11.6 Cardiovascular Diseases Revenue Growth (2013-2018)
    • 11.7 Kidney Diseases Revenue Growth (2013-2018)
    • 11.8 Others Revenue Growth (2013-2018)

    12 Global Oligonucleotide Therapeutics Market Size Forecast (2018-2023)

    • 12.1 Global Oligonucleotide Therapeutics Market Size Forecast (2018-2023)
    • 12.2 Global Oligonucleotide Therapeutics Market Forecast by Regions (2018-2023)
    • 12.3 North America Oligonucleotide Therapeutics Revenue Market Forecast (2018-2023)
    • 12.4 Europe Oligonucleotide Therapeutics Revenue Market Forecast (2018-2023)
    • 12.5 Asia-Pacific Oligonucleotide Therapeutics Revenue Market Forecast (2018-2023)
    • 12.6 South America Oligonucleotide Therapeutics Revenue Market Forecast (2018-2023)
    • 12.7 Middle East and Africa Oligonucleotide Therapeutics Revenue Market Forecast (2018-2023)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Oligonucleotide therapeutics are different from conventional medicine as they can inhibit the expression of certain genes. This has given rise to innovative new oligonucleotides that can target specific genes and treat chronic diseases. The development of oligonucleotide therapeutics is done through chemically modified artificial nucleic acids. The artificial oligonucleotides are being developed which has improved in vivo stability and enhanced affinity to target mRNA.

      Scope of the Report:

      This report studies the Oligonucleotide Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Oligonucleotide Therapeutics market by product type and applications/end industries.

      Asia-Pacific is the fastest growing region as several oligonucleotide therapeutics manufacturers are looking forward to establishing manufacturing facilities in this region. Moreover, research undertaking and funding in the synthesis of oligonucleotides are expected to add on to the increasing demand.

      The global Oligonucleotide Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Oligonucleotide Therapeutics.

      Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

      Market Segment by Companies, this report covers

      Pfizer

      Merck

      Biogen

      PCI Biotech

      SomaGenics

      ContraVir

      Alnylam

      Regulus Therapeutics

      Ionis Pharmaceuticals

      Gilead

      Santaris Pharma

      Market Segment by Regions, regional analysis covers

      North America (United States, Canada and Mexico)

      Europe (Germany, France, UK, Russia and Italy)

      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

      South America (Brazil, Argentina, Colombia)

      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers

      Antisense

      Ribozymes

      Aptamers

      miRNA

      CpG/Immunostimulatory

      RNAi

      Others

      Market Segment by Applications, can be divided into

      Infectious Diseases

      Oncology

      Neurodegenerative Disorders

      Cardiovascular Diseases

      Kidney Diseases

      Others




      Summary:
      Get latest Market Research Reports on Oligonucleotide Therapeutics . Industry analysis & Market Report on Oligonucleotide Therapeutics is a syndicated market report, published as Global Oligonucleotide Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023. It is complete Research Study and Industry Analysis of Oligonucleotide Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,480.00
      $5,220.00
      $6,960.00
      2,336.82
      3,505.23
      4,673.64
      3,202.30
      4,803.44
      6,404.59
      421,567.20
      632,350.80
      843,134.40
      230,770.63
      346,155.95
      461,541.26
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report